NCT03295227 2026-01-30
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
M.D. Anderson Cancer Center
Novartis
Ohio State University Comprehensive Cancer Center
National Cancer Center, Japan
Georgetown University